Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Koffiekamer  /  Moderna, Novavax, Inovio, BioNtech, 'RNA vaccin-producenten'

Ontvang nu dagelijks onze kooptips!

word abonnee

Koffiekamer« Terug naar discussie overzicht

Moderna, Novavax, Inovio, BioNtech, 'RNA vaccin-producenten'

819 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 41 »» | Laatste | Omlaag ↓
  2. forum rang 5 MisterBlues 5 augustus 2020 17:06
    Moderna vanwege de versnelde mRNA techniek en de subsidie.
    BioNtech zelfde reden als boven plus de ondersteuning van big Pharma
    Cydy staat boven aan de voedselketen als het om vernieuwing gaat
    Relief toont effectiviteit aan in fase 2b/3

    Novavax heb ik juist gemist - zoals geschreven. Ik zou het graag hebben omdat ze 10.000 antistoffen in primaten kunnen produceren en veel subsidie krijgen.

    PDSB zie ik nog niets dat fundamenteel gesproken eruit springt, terwijl ze een extreem slecht trackrecord hebben.

    Universeel flu vaccin klinkt goed maar...twijfelachtig.

    Ik denk dat ik even wacht met kopen totdat ik weet wat de veiligheidsgegevens zijn van fase 1.
  3. forum rang 5 MisterBlues 5 augustus 2020 17:15
    The Coalition for Epidemic Preparedness Innovations (CEPI) was established in 2017 to fund vaccine efforts to stop worldwide epidemics. Co-founded by Bill Gates, the nonprofit is the largest vaccine initiative charity in the world. In May, CEPI made headlines when it granted its largest award ever, $388 million, to tiny Novavax (NASDAQ:NVAX) to help the biotech develop a vaccine candidate for COVID-19.

    Operation Warp Speed (OWS) was created after COVID-19 became a health emergency in the U.S. The idea was to fund multiple vaccine candidates and speed up the drug development process to create a working vaccine as fast as possible. In June, OWS narrowed its favorite vaccine candidates down to five companies: Moderna (NASDAQ:MRNA), Merck (NYSE:MRK), Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), and AstraZeneca (NYSE:AZN). But in July, OWS shocked the world by instead granting $1.6 billion in funding to tiny Novavax.

    Novavax's vaccine candidate has produced a huge number of antibodies in nonhuman primates

    The decision to send $1.6 billion to Novavax was not made simply because Novavax is a small company. And it was not made just because management has friendly relations with CEPI.

    The simplest explanation is probably the best one. The federal government really wants a working COVID-19 vaccine. This is why it's granting such high dollar amounts in the first place. And science doesn't play favorites. Novavax was selected for a $1.6 billion grant not because it's a small company or enjoys favoritism. Novavax won that grant because its animal data is the most promising of all the vaccine candidates to date.

    Back in June, Novavax announced its animal data for its vaccine candidate, NVX-CoV2373. "We are seeing neutralizing titers in the 10,000 range in nonhuman primates," said Dr. Gregory Glenn, the head of research and development at Novavax. Other companies are reporting antibody data in the 40 to 200 range in animal testing.

    As a point of contrast, earlier this month Pfizer and its partner, BioNTech (NASDAQ:BNTX), announced that in a phase 1 trial, 10 micrograms of its vaccine candidate produced an average of 168 antibodies in humans, while a dose of 30 micrograms yielded 267.

    While Novavax has not released its phase 1 data as applies to humans yet, a vaccine candidate that produces 10,000 antibodies in primates is very impressive. It's likely why the company was awarded almost $2 billion in grant funding.

    We're anxious to see whether this impressive result in animal testing can be reproduced in humans.

    www.fool.com/investing/2020/07/22/why...
  4. forum rang 5 MisterBlues 5 augustus 2020 17:36
    It did not demonstrate CD8 T cell response which is critical for long term immunity to coronaviruses. Read here: www.ncbi.nlm.nih.gov/pmc/articles/PMC... The vaccine is useless if it only provides a few weeks of protection. Additionally, it needs to prove that it can cover the mutations as INO has.

    Humans are highly susceptible to infection with respiratory viruses including respiratory syncytial virus (RSV), influenza virus, human metapneumovirus, rhinovirus, coronavirus, and parainfluenza virus. While some viruses simply cause symptoms of the

    Humans are highly susceptible to infection with respiratory viruses including respiratory syncytial virus (RSV), influenza virus, human metapneumovirus, rhinovirus, coronavirus, and parainfluenza virus. While some viruses simply cause symptoms of the

    Humans are highly susceptible to infection with respiratory viruses including respiratory syncytial virus (RSV), influenza virus, human metapneumovirus, rhinovirus, coronavirus, and parainfluenza virus. While some viruses simply cause symptoms of the

    www.ncbi.nlm.nih.gov
  5. forum rang 5 MisterBlues 5 augustus 2020 18:34
    VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development

    Government of Canada will support advancement of VBI’s coronavirus program through Phase 2 clinical development

    Pre-clinical data are expected to enable selection of clinical candidates in Q3 2020 and the initiation of clinical studies by the end of 2020
  8. forum rang 5 MisterBlues 6 augustus 2020 11:13

    Each of the vaccine companies executives have said emphatically that the hardest part of this Vaccine creation process is ramping up the manufacturing.

    There are only so many 4000 liter and 2000 liter capable manufacturers. When they have reached their capacity - that is it. Whichever company strikes a deal/contract with them first gets priority. A company may have a viable candidate but, may not get enough if it made if they don’t lock down manufacturing contracts.

    These are the manufactures that Novavax has signed production contracts with!!!

    1.)
    AGC Biologics' global network spans three continents, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.

    2.)
    Emergent Biosolutions Locations
    * Gaithersburg, US (HQ) 400 Professional Dr #400.
    * Baltimore, US. 1111 S Paca St.
    * Baltimore, US. 5901 E Lombard St.
    * Hattiesburg, US. 46 Shelby Thames Dr.
    * Lansing, US. 3500 N Martin Luther King Jr Blvd.
    * Seattle, US. 2401 4th Ave #1050.

    3.)
    Polypeptide Group
    Sweden
    France
    Belgium
    LA
    San Diego

    4.) Catalent/Paragon
    needs of new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates.
    NORTH AMERICA
    Baltimore, USA
    Bloomington, USA
    Catonsville, USA
    Emeryville, USA
    Gaithersburg, USA
    Harmans/BWI, USA
    Houston, USA
    Kansas City, USA
    Madison, USA
    Morrisville/RTP, USA
    Rockville, USA
    EUROPE
    Anagni, Italy
    Brussels, Belgium
    Gosselies, Belgium
    Limoges, France

    FUJIFILM/Diosynth locations
    FUJIFILM Diosynth Biotechnologies is a leading contract development and manufacturing organization (CDMO) providing process development and manufacturing of biologics at four locations:
    * College Station / Texas, USA.
    * Hillerød / Denmark.
    * Research Triangle Park / North Carolina, USA.
    * Teesside / UK.

    Not to be outdone in 2019, FUJIFILM acquired Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located near Copenhagen, Denmark

    Cadila
    India

    Serum Institute of India
    India

    Praha (Novavax owned)
    Czech Republic
  9. [verwijderd] 6 augustus 2020 13:28
    Arbutus to Report Second Quarter 2020 Financial Results
    GlobeNewswire
    Arbutus Biopharma Corporation
    ,GlobeNewswire•July 29, 2020
    WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020. The schedule for the press release and conference call/webcast are as follows:

    • Q2 2020 Press Release: August 7, 2020 at 7:30 a.m. ET
    • Q2 2020 Conference Call/Webcast: August 7, 2020 at 8:45 a.m. ET
    • Domestic Dial-In Number: (866) 393-1607
    • International Dial-In Number: (914) 495-8556
    • Conference ID Number: 4974547
    A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast.

    Morgen voorbeurs, 13.30 nl-tijd. Gaat vandaag wel wat reuring geven.
  11. forum rang 5 MisterBlues 6 augustus 2020 16:04
    quote:

    hosternokke schreef op 6 augustus 2020 13:28:

    Arbutus to Report Second Quarter 2020 Financial Results
    GlobeNewswire
    Arbutus Biopharma Corporation
    ,GlobeNewswire•July 29, 2020
    WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020. The schedule for the press release and conference call/webcast are as follows:

    • Q2 2020 Press Release: August 7, 2020 at 7:30 a.m. ET
    • Q2 2020 Conference Call/Webcast: August 7, 2020 at 8:45 a.m. ET
    • Domestic Dial-In Number: (866) 393-1607
    • International Dial-In Number: (914) 495-8556
    • Conference ID Number: 4974547
    A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast.

    Morgen voorbeurs, 13.30 nl-tijd. Gaat vandaag wel wat reuring geven.
    Het blijft interessant:

    With major pharma using mrna technology to develop vaccines you would think that ARbutus would be trading multiples higher than todays price. Must stay patient cause when the general investing public gets a sniff of who was initially behind mRna technology there will be no stopping ABUS. Patent was upheld in courts as belonging to ABUS [through subsidiary's]. It was Tekmira in 2013 that first invented LNP delivery system in trying to develop an Ebola vaccine. As you know Tekmira is now Arbutus.
  12. forum rang 5 MisterBlues 7 augustus 2020 08:46
    Pfizer CEO: We’ll Know By October Whether Covid-19 Vaccine Works

    Bruce JapsenSenior Contributor
    Healthcare
    Albert Bourla said the safety and efficacy of its experimental vaccine for the ... [+]

    Pfizer chief executive Albert Bourla said Thursday clinical trials should reveal by October whether the company’s vaccine against the Coronavirus strain Covid-19 is safe and effective.
    The top executive at one of the world’s largest drug makers said the 30,000 patients in a final-stage “phase 3” clinical trial for its Covid-19 vaccine should be enrolled by the end of August. Enrollment in phase 3 clinical trials for Pfizer’s vaccine and another in development from Moderna began in July. Half, or about 15,000, in each company’s trials are getting the vaccine while the other 15,000 are receiving placebo.
    “October is coming,” Bourla said Thursday afternoon in an interview with the Washington Post Live. “In October, the truth will be revealed.”

    The update from Pfizer comes less than a month after the U.S. Department of Health and Human Services and the Department of Defense announced a $1.95 billion agreement with Pfizer and its German biotech partner to deliver 100 million doses of a Covid-19 vaccine by December. The agreement announced July 22 also allows the U.S. government to acquire an additional 500 million doses.
    On Thursday, Bourla said Pfizer, which is working with the Germany biotech company BioNTech to develop Covid-19 investigational vaccines, expects to submit a vaccine to the U.S Food and Drug Administration in October for possible approval. That will then trigger what is expected to be an expedited approval process that could even win Pfizer’s vaccine an emergency use authorization based on comments FDA commissioner Dr. Stephen Hahn made last week.

    In an interview last week with JAMA, Hahn said the FDA would “consider an emergency use authorization if we felt that the risks associated with the vaccine were much lower than the risks of not having a vaccine and the potential benefit of having a vaccine.”

    Both the Moderna and Pfizer-BioNTech products are using a new technology that those involved say speeds the development and manufacturing of the vaccines. Both use a synthetic version of genetic material known as messenger RNA, or mRNA, that teaches the patient’s immune system to recognize - and then attack - the coronavirus Covid-19.

    In the Pfizer vaccine, Bourla said it will require two doses 21 days apart. Over time, the technology allows for a patient to get a boost of the vaccine if needed to protect against the virus.

    “We will follow the patients for two years,” Bourla said in the Washington Post Live interview. “If the virus changes this technology allows us to change the vaccine in weeks rather than months.”

  15. forum rang 5 MisterBlues 10 augustus 2020 11:23
    quote:

    Eis2020 schreef op 10 augustus 2020 09:23:

    biopharmajournal.com/2020/08/07/versa...
    Versamune-CoV-2 (PDS0203) from PDS Biotechnology Corp (NASDAQ:PDSB) Demonstrates High Levels Of Robust, Long-Lasting CD8 (Killer) T-Cell Responses against COVID-19
    The mystery of how long the COVID-19 pandemic will last remains unresolved. The world continues to report increased deaths and the rapid spread of the virus. However, hundreds of pharmaceutical companies have responded to the need for an emergency solution. With so many trial vaccines under development, PDS Biotechnology Corp (NASDAQ: PDSB) Corporation has presented preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203).

    Het is nog maar pre-klinisch. Weet jij hoeveel biotech bedrijven actief zijn op basis van een goede aanwijzing in modellen of testopstellingen of bio-technische platforms (Versamune)

    www.prnewswire.com/news-releases/fda-...

    covid-19tracker.milkeninstitute.org/
  17. Sub!et 10 augustus 2020 12:28
    quote:

    MisterBlues schreef op 10 augustus 2020 12:19:

    Als deze naar de beurs gaat dan weet ik het wel.

    www.curevac.com/about-curevac
    Kan idd interssant worden.
    Bedankt.

    GSK buys 10% of CureVac in vaccine tech deal
    Pushkala Aripaka, Arno Schuetze
    3 MIN READ
    (Reuters) - GSK (GSK.L) is to buy a 10% stake in German biotech company CureVac for 130 million pounds ($163.67 million), the two companies said on Monday, in a deal that bets on new technologies already being used in potential COVID-19 vaccines.

    GSK and CureVac, backed by Microsoft billionaire Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases, they said.
    The deal points to a valuation of more than $1.6 billion for CureVac as it prepares for a stock market launch this year.

    For GSK, the world’s biggest vaccine maker, it adds to the company’s raft of investments in technologies that may fight future outbreaks.
    mRNA vaccines use ribonucleic acid (RNA), a chemical messenger that evokes an immune response when injected by instructing cells to make proteins that mimic pathogens.
    The approach, also being deployed in experimental COVID-19 vaccines by BioNTech and partner Pfizer (PFE.N) and Moderna (MRNA.O), is yet to be approved in any therapy.
    “CureVac’s experience complements our own expertise,” said Roger Connor, President of GSK Vaccines.
    GSK shares fell 1.6% to 1,633.2 pence by 0743 GMT.
    After a 300 million euro ($343.77 million) investment by the German government CureVac had planned to list on Nasdaq this month, a document seen by Reuters in June showed.
    It has since received 75 million euros in European funding, in addition to the GSK boost.
    CureVac is now planning a stock market listing in September or October, led by Bank of America (BAC.N), Credit Suisse (CSGN.S) and Jefferies (JEF.N), which is likely be able to command a similar valuation to that signalled by GSK’s investment, people familiar with the matter said.
    CureVac declined to comment on the IPO but said it remained open to all financing options. The banks declined to comment or were not immediately available for comment.

    www.reuters.com/article/us-gsk-cureva...
  18. forum rang 5 MisterBlues 11 augustus 2020 00:26
    5 Things That Could Go Wrong With A Coronavirus Vaccine

    Robert Pearl, M.D.Contributor
    Healthcare

    We're still in the early stages of Covid-19 vaccine development.
    Joe Raedle/Getty Images
    According to Dr. Anthony Fauci, the nation’s top infectious disease expert, a coronavirus vaccine could be ready for distribution within months.
    “We feel cautiously optimistic that we will have a vaccine by the end of this year and as we go into 2021,” he told lawmakers on July 31, adding, “the plans now allow for any American who needs a vaccine to get it within the year 2021.”
    Researchers are working at breakneck speeds on more than 165 vaccines for Covid-19. At present, more than two dozen are in phases two or three of testing, which include human trials. Though early results look promising, a lot can still go wrong, such as:

    1. Americans might not take it
    Assuming a Covid-19 vaccine meets FDA and WHO benchmarks, which include such stipulations as “vaccine benefits outweigh safety risks,” the public still needs to be convinced to take the shot. That’s not a given.
    In May, an Associated Press poll found less than 50% of Americans planned to take an approved and available Covid-19 vaccine, similar to the findings of a Pew Research Center poll conducted later that month.
    The most recent numbers show patients and healthcare professionals are divided on the issue of when and if to get vaccinated. The opinion poll, made available to the 10,000-plus subscribers of Monthly Musings on American Healthcare asked: “At what point would you feel comfortable getting vaccinated for Covid-19?”

    According to the results, more than half of people working in healthcare would be willing to get vaccinated upon FDA approval. In contrast, 61% of patients prefer to wait for more definitive proof of the vaccine’s safety and efficacy.
    That would present a problem. To eliminate the virus, nearly all the U.S. population needs to be vaccinated or acquire antibodies through infection and recovery. Otherwise, the disease will simmer indefinitely.

    2. Immunity might not last
    Historically, some strains of coronavirus, like the kind that causes the common cold, fail to produce long-lasting antibodies. By contrast, people who recover from the more lethal coronaviruses, such as severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), produce antibodies that last two to three years.
    So what about SARS-CoV-2, the virus causing the current pandemic? Results of a study published in Nature observed that antibody levels fall off just two to three months after infection. Likewise, a New England Journal of Medicine report last month noted antibody levels in Covid-19 survivors dropped rapidly within months. That same report suggested people who recover from the disease could be left without any antibodies within one year.
    As scientists seek to better understand the immune status of people who recover from Covid-19, much remains unknown. Do lower antibody counts indicate the end of immunity? How will these antibodies respond when re-exposed to the virus and are antibody levels higher in people who had severe infection? Also, is a second illness from Covid-19 possible or were past scares of reinfection merely the result of faulty antibody (serology) testing?
    With so much confusion surrounding the immune status of people who’ve recovered from the infection itself, scientists fear there will be even less certainty concerning a vaccine’s true efficacy.

  19. forum rang 5 MisterBlues 11 augustus 2020 00:26
    3. The vaccine might not work
    The U.S. government’s Operation Warp Speed, which launched in June, pledged $10 billion toward developing and delivering 300 million doses of a safe, effective Covid-19 vaccine by January 2021. The race is on and some early leaders have drummed up significant media excitement over the possibility of bringing a vaccine to market in record time.
    As I wrote in Forbes last month, Americans assume a cure will materialize from a combination of public urgency and heavy research funding. Few realize that the currently accepted timeline for a coronavirus vaccine is based more on medical optimism than scientific evidence.
    Major drug companies like J&J, Pfizer and Moderna—all vying to produce a Covid-19 cure—are relying on a method that has not produced a safe or effective mRNA vaccine against any viral infection in more than two decades of research.

    4. The vaccine gets approved but might be only 50% effective
    In the past, successfully developed vaccines used inactivated or attenuated (weakened) viruses and proved highly effective. For example, three doses of the polio vaccine is nearly 100 percent effective while the vaccine for measles is 93 percent effective after just one dose (and 97%-plus after two doses), according to the CDC.
    Many vaccines, however, aren’t designed to deliver lifelong protection at near-universal rates. For example, the CDC conducts studies each year about the effectiveness of the seasonal flu shot at protecting people against various strains. And because the flu virus mutates from year to year, statistics show the vaccine is between 40% to 60% effective at reducing the risk of flu-like illness.
    That brings us to the novel coronavirus. In April, the WHO noted the ideal vaccine would establish immunity in at least 70 percent of the population, including the elderly. In July, an FDA official added, “We’re going to need a vaccine that’s probably in the order of 70% effective and 70%, at least, of the population is going to need to take it.” Meanwhile, Dr. Fauci is on the record as saying that he, too, would settle for a 70% to 75% effective vaccine.
    But those are all “ideal” situations. =FDA guidance issued in June stated, “To ensure that a widely deployed COVID-19 vaccine is effective, the primary efficacy endpoint point estimate for a placebo-controlled efficacy trial should be at least 50%.”
    This possibility leads to some disheartening mathematics. Assuming that only 50% of the population takes a vaccine that is only 50% effective, the nation’s immunization rate could be as low as 25%. That total would be insufficient to end the pandemic.
    Achieving herd immunity, the point at which the virus would no longer spread, would require at least 70% of the country (200 million Americans) to either be vaccinated or acquire the virus and recover from it. Further, that estimate assumes long-lasting immunity from the virus.

    5. Something unexpected happens
    For all that scientists don’t know about Covid-19 (the disease), they do know that the coronavirus (which causes the disease) has behaved predictably over the past six months—far more predictably than humans.
    When people wear masks, physically distance and wash their hands, the curve of infection either flattens or declines. When people gather indoors or in large groups without masks, cases rise exponentially.
    In that respect, we’ve seen no major surprises out of the pathogen so far. But could that change, too?
    Immunologists have observed that the virus has exhibited no major or concerning mutations since reaching U.S. shores. But, theoretically, it could. And a virus that mutates significantly over time could render an approved vaccine ineffective.
    Also, what about our presently optimistic scenarios for vaccine trials? Though public health experts continue to push the narrative of having an FDA-approved vaccine by 2021, there’s an important number that goes continually overlooked: Four. As in four years, which is the fastest a successful vaccine has ever been developed (mumps). Nearly all vaccines take five years or much longer.
    Finally, there’s a big difference between having a vaccine ready to go and being able to manufacture or administer enough doses for hundreds of millions of Americans. From scaling up the production to meeting global demands to deciding which populations should get it first, plenty of potential roadblocks remain.
    If any of these unexpected scenarios were to occur, our nation could end up reaching herd immunity (and ending the pandemic) through infection, not vaccination.
    Such a scenario—one in which there is no safe, effective, long-lasting vaccine—would be ugly. It would likely involve keeping current restrictions on businesses, schools and public gatherings in place (to avoid overwhelming critical care units). But it would also involve a prolonged coronavirus recession, worsening mental health problems and rising death tolls—perhaps hundreds of thousands more.
    As the world’s leading virologists and immunologists plan for, and do everything possible to avoid, these worst-case scenarios, Americans are left with little choice but to root for a vaccine and hope Dr. Fauci’s “cautious optimism” holds true.
  20. forum rang 5 MisterBlues 11 augustus 2020 19:59
    BEVERLY HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP). SteraMist announces early stage trials of SteraBot, its first-generation technology disinfection robot jointly developed in Hong Kong with RV Automation Technology Co. Ltd.

    The outbreak of COVID-19 has continued to seriously affect the daily lives of citizens and the economies of every country around the globe. Recent sharp surges in diagnosed cases in many locations mean that global efforts to break the chains of new coronavirus transmissions and the urgent development of new vaccines continue unabated. As the epidemic escalates the potential roles of robotics are becoming increasingly prominent. Disinfection robots have the potential to be deployed as effective resources to combat the spread of COVID-19. Robotic applications using TOMI SteraMist iHP™ technology in healthcare and many other industries will help to vastly reduce direct human exposure to dangerous pathogens.

    TOMI has signed agreements with several companies in the Asia and Southeast Asia region granting the right of its patented SteraMist iHP™ for use in the development of disinfection robots to tackle the growing threat of COVID-19. Prototype disinfection robots have been developed and are undergoing early stage trials at various locations. One of TOMI’s robotic development partners, RV Automation Technology Company Limited, is working with the Prevention and Control of Coronavirus Disease 2019 project sponsored by the Innovation and Technology Fund, Innovation and Technology Commission, the Government of Special Administrative Region of Hong Kong.

    TOMI is also working with other companies in both Singapore and Hong Kong to develop flexible robotic solutions for deployment in healthcare, maritime and hospitality sectors.

    The new disinfection robot will leverage on latest technologies in Automatic Guided Vehicle and will be able to map a new environment, perform autonomous navigation and conduct disinfection routines based on proprietary algorithms. Software development by TOMI’s robotic partners provide an enhanced AI capability to optimize mapping, navigation and ensuring SteraMist iHP™ disinfection efficacy achieved under the operating perimeters prescribed by TOMI. Extensive trials of the prototype disinfection robots cover key considerations such as operational safety protocols, post verification of disinfection efficacy, quality control, product reliability and maximizing smooth implementation under different environments.

    TOMI believes that the global demand of disinfection robots from customers will continue to increase firmly over the coming period. Robotic application of SteraMist iHP™ eliminates the pitfalls of manual operation by users. Our robotic R&D strategy will allow TOMI to expand business opportunity with its new product range to meet the urgent disinfection needs of customers across a wide spectrum of industries globally. We expect that the future successful development of SteraMist iHP™ robots will serve to propel and sustain business growth and profitability for our shareholders in the new technology era.

    TOMI CEO, Dr. Halden Shane, states: “With the completion of research efforts, we expect to meet the increasing needs and requests by our clients to have a disinfecting robot that eliminates manual cleaning inconsistencies from their disinfection protocol, SteraBot achieves that task. One of our major real estate group customers currently has deployed over 10 different types of industrial robots in its existing fleet. This customer has already expressed keen interest in SteraMist iHP™? robots. They believe that the introduction and adoption of new robotic technology will better protect the safety of their workers and improve the group’s capabilities to combat the epidemic today and in the future.”

    TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

    TOMI™ Environmental Solutions, Inc. (OTCQB:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
819 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 41 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 874,02 0,00%
EUR/USD 1,0712 +0,13%
FTSE 100 8.040,38 0,00%
Germany40^ 18.036,80 -0,29%
Gold spot 2.318,60 +0,11%
NY-Nasdaq Composite 15.712,75 +0,10%

Stijgers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Dalers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!